ES2150894T1 - Vector de baculovirus modificado por proteinas de envoltura para terapia genica. - Google Patents

Vector de baculovirus modificado por proteinas de envoltura para terapia genica.

Info

Publication number
ES2150894T1
ES2150894T1 ES98947386T ES98947386T ES2150894T1 ES 2150894 T1 ES2150894 T1 ES 2150894T1 ES 98947386 T ES98947386 T ES 98947386T ES 98947386 T ES98947386 T ES 98947386T ES 2150894 T1 ES2150894 T1 ES 2150894T1
Authority
ES
Spain
Prior art keywords
proteins
wrapping
gene therapy
baculovirus vector
vector modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES98947386T
Other languages
English (en)
Inventor
Christian Hofmann
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HepaVec AG fur Gentherapie
Original Assignee
HepaVec AG fur Gentherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HepaVec AG fur Gentherapie filed Critical HepaVec AG fur Gentherapie
Publication of ES2150894T1 publication Critical patent/ES2150894T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1. Vector, que consta de un baculovirus, que contiene los siguientes componentes: - proteínas de envoltura de virus modificadas, - una secuencia heteróloga de ADN, - un promotor para la expresión en células de mamíferos.
ES98947386T 1997-08-15 1998-08-05 Vector de baculovirus modificado por proteinas de envoltura para terapia genica. Pending ES2150894T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1997135593 DE19735593C2 (de) 1997-08-15 1997-08-15 Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie

Publications (1)

Publication Number Publication Date
ES2150894T1 true ES2150894T1 (es) 2000-12-16

Family

ID=7839201

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98947386T Pending ES2150894T1 (es) 1997-08-15 1998-08-05 Vector de baculovirus modificado por proteinas de envoltura para terapia genica.

Country Status (6)

Country Link
EP (1) EP1003896A1 (es)
JP (1) JP2003530064A (es)
CA (1) CA2300362A1 (es)
DE (1) DE19735593C2 (es)
ES (1) ES2150894T1 (es)
WO (1) WO1999009193A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002014527A2 (en) * 2000-08-11 2002-02-21 Boyce Thompson Institute For Plant Research, Inc. Gp64-null baculoviruses pseudotyped with heterologous envelope proteins
CA2440342A1 (en) 2001-03-12 2002-09-19 Ark Therapeutics Ltd. Avidin-pseudotyped viral vectors and their use
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
WO2004029259A1 (ja) * 2002-09-25 2004-04-08 Osaka Industrial Promotion Organization バキュロウイルスベクター、バキュロウイルスベクター製造方法及び遺伝子導入方法
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
GB0425739D0 (en) * 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
CN102719366B (zh) 2004-12-22 2014-07-16 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006315347A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
EP3225248B1 (en) 2008-07-23 2023-06-07 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
DK2605789T3 (da) 2010-08-17 2019-09-16 Ambrx Inc Modificerede relaxinpolypeptider og anvendelser deraf
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JPWO2016059911A1 (ja) * 2014-10-17 2017-07-27 国立大学法人金沢大学 マラリアワクチン
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
AU702830B2 (en) * 1994-09-23 1999-03-04 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system

Also Published As

Publication number Publication date
DE19735593A1 (de) 1999-02-18
JP2003530064A (ja) 2003-10-14
DE19735593C2 (de) 1999-08-26
WO1999009193A1 (de) 1999-02-25
EP1003896A1 (de) 2000-05-31
CA2300362A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
ES2150894T1 (es) Vector de baculovirus modificado por proteinas de envoltura para terapia genica.
ES2065919T3 (es) Ribozimas.
AR008508A1 (es) METODO PARA LOGRAR UNA EXPRESION ESPECíFICA MESoFILA DE UNA SECUENCIA DE NUCLEOTIDOS CODIFICANTE EN PLANTAS, CONTROLADA POR UN PROMOTOR , CASETES DE EXPRESION, VECTORES RECOMBINANTES Y MICROORGANISMOS QUE CONTIENEN DICHOS PROMOTORES, UTILIZACION DE DICHOS VECTORES Y PROMOTORES Y PROCEDIMIENTO PARA P
FI961146A0 (fi) Adenoassosioituja virusliposomeja ja niihin liittyviä menetelmiä
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
ES2042693T3 (es) Formulaciones proteinicas de plasma y recombinantes en medios de baja potencia ionica.
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
BR9813369A (pt) Amortecedor para uso em uma sola de sapato, e, sola de sapato.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
ES2146775T3 (es) Tratamiento de terapia genica de enfermedades del sistema nervioso central (snc) mediante un principio activo especifico de las celulas e independiente del ciclo celular.
ATE270342T1 (de) Endosomolytisch wirksame partikel
AR014891A1 (es) Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
PT1021553E (pt) Cassette de expressao eucariotica de genes e suas utilizacoes
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
AU2520595A (en) Virosome-mediated intracellular delivery of therapeutic agents
PT1212428E (pt) Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores
ES2165050T3 (es) Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos.
ES8506113A1 (es) Un metodo de electrodepositar una superficie electroconductora que sirve como electrodo
DK0986568T3 (da) Kationiske midler til transfektion af nukleinsyrer
AR013853A1 (es) Un metodo para aumentar la expresion transgenica en una poblacion de celulas de monocotiledoneas y poblacion de celulas de monocotiledoneas conexpresion transgenica aumentada.
DK0870015T3 (da) Xylanaser, gener, der koder for disse, samt anvendelser deraf
DK0528925T3 (da) Klonings- og/eller ekspressionsvektorer, deres fremstilling og anvendelse
AU6363486A (en) Promoter arrangement for streptomycetes vectors
IT1177378B (it) Vettore plasmidico psm112 ad espressione in bacillus subtilis